Renalytix Plc (RNLXY)

OTCMKTS · Delayed Price · Currency is USD
0.2200
-0.0200 (-8.33%)
Sep 17, 2025, 1:40 PM EDT
-8.33%
Market Cap33.03M
Revenue (ttm)2.89M
Net Income (ttm)-28.16M
Shares Outn/a
EPS (ttm)-0.22
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume102,035
Average Volume110,314
Open0.2300
Previous Close0.2400
Day's Range0.1918 - 0.2300
52-Week Range0.1200 - 0.3236
Beta1.55
RSI62.52
Earnings DateSep 26, 2025

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, pa... [Read more]

Sector Healthcare
Founded 2018
Employees 102
Stock Exchange OTCMKTS
Ticker Symbol RNLXY
Full Company Profile

Financial Performance

In 2024, Renalytix's revenue was $2.29 million, a decrease of -32.74% compared to the previous year's $3.40 million. Losses were -$33.46 million, -26.64% less than in 2023.

Financial Statements

News

Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease

Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes NEW YORK , Sept. 15, ...

3 days ago - PRNewsWire

MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities

New partnership expands access to prognostic testing for people with diabetic kidney disease, helping improve lives and reduce health disparities. NEW YORK , July 21, 2025 /PRNewswire/ -- Renalytix Pl...

2 months ago - PRNewsWire

Renalytix Plc (RNLXY) Q2 2025 Earnings Call Transcript

Renalytix Plc (OTC:RNLXY) Q2 2025 Earnings Conference Call March 18, 2025 10:00 AM ET Company Participants Julian Baines - Executive Chairman Fergus Fleming - Chief Technology Officer James McCullough...

6 months ago - Seeking Alpha

Renalytix plc Reports Financial Results for First Quarter of Fiscal Year 2025

LONDON and NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management...

10 months ago - PRNewsWire